CompletedNCT05686239
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
Researchers compared RL-007 (Inidascamine) and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Medication studyAges 18–55Multiple countries
Understand this study
What did researchers investigate?
Researchers compared RL-007 (Inidascamine) and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Culver City and 35 more locationsSee all locations and recruitment
- Treatment duration
- 6 weeks
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: December 8, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 242
- Sponsor
- Recognify Life Sciences
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Bulgaria, Czechia, ...
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT05686239
- Official title
Show the full official title
An Adaptive, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
Get this study by email
Recruitment & locations
CompletedCulver City, United States · Garden Grove, United States · Lafayette, United States
32 more locations
- Oceanside, United States
- Orange, United States
- Torrance, United States
- Hialeah, United States
- Miami, United States
- Miami Lakes, United States
- Atlanta, United States
- Augusta, United States
- Gaithersburg, United States
- Berlin, United States
- Brooklyn, United States
- Chapel Hill, United States
- Cincinnati, United States
- Cleveland, United States
- Dallas, United States
- Houston, United States
- Everett, United States
- Burgas, Bulgaria
- Kardzhali, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Pilsen, Czechia
- Prague, Czechia
- Gdansk, Poland
- Gorlice, Poland
- Kielce, Poland
- Lodz, Poland
- Lublin, Poland
- Poznan, Poland
- Czechia
Questions about this study
What did researchers investigate?
Researchers compared RL-007 (Inidascamine) and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Who is behind this study?
The study sponsor is Recognify Life Sciences.
Did this study involve medication?
Yes. The study involved medication, including RL-007 (Inidascamine) and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia